NASDAQ:PSTX • US73730P1084
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for POSEIDA THERAPEUTICS INC (PSTX).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2024-11-26 | William Blair | Downgrade | Outperform -> Market Perform |
| 2024-11-26 | BTIG | Downgrade | Buy -> Neutral |
| 2024-11-26 | HC Wainwright & Co. | Downgrade | Buy -> Neutral |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-11-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-30 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-17 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-06 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-07-25 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-05-02 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-22 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-03-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-12-11 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-12-11 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2023-10-10 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-08-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-23 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2023-05-10 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-03-10 | HC Wainwright & Co. | Reiterate | Buy |
| 2023-02-23 | HC Wainwright & Co. | Maintains | Buy |
| 2023-02-01 | Cantor Fitzgerald | Reiterate | Overweight |
| 2023-01-04 | HC Wainwright & Co. | Initiate | Buy |
| 2022-08-09 | Piper Sandler | Maintains | Overweight |
| 2022-05-13 | Piper Sandler | Maintains | Overweight |
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 31.2M | 130.5M 318.27% | 64.703M -50.42% | 150.06M 131.92% | 44.2M -70.55% | 22.44M -49.23% | 103.83M 362.70% | 386.97M 272.70% | 822.57M 112.57% | 1.184B 43.94% | 1.503B 26.94% | 1.713B 13.97% | |
| EBITDA YoY % growth | -136.85M -10.44% | -54.73M 60.01% | -123.89M -126.37% | -125.266M -1.11% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -141.4M -11.78% | -59.9M 57.64% | -129.504M -116.20% | -95.307M 26.41% | -216.353M -127.01% | -276.538M -27.82% | -219.467M 20.64% | 51.248M 123.35% | 380.52M 642.51% | 633.64M 66.52% | 852.9M 34.60% | 968.96M 13.61% | |
| Operating Margin | -453.21% | -45.90% | -200.15% | -63.51% | -489.49% | -1,232.35% | -211.37% | 13.24% | 46.26% | 53.52% | 56.75% | 56.57% | |
| EPS YoY % growth | -2.02 36.12% | -1.09 46.04% | -1.39 -27.52% | -0.97 30.29% | -1.72 -77.11% | -1.41 17.78% | -1.19 15.42% | 0.23 119.66% | 1.68 617.39% | 2.79 66.06% | 3.08 10.22% | 3.48 12.91% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.37 -36.00% | -0.48 -90.40% | -0.52 -61.50% | -0.48 -326.67% | -0.39 -5.56% | -0.22 52.86% | -0.22 56.58% | -0.23 50.71% | -0.23 39.47% |
| Revenue Q2Q % growth | 17.34M -30.63% | 7.65M -72.82% | 7.65M -70.55% | 7.65M -89.34% | 7.65M -55.88% | N/A | N/A | N/A | N/A |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -37.738M -45.65% | -42.84M -74.31% | -48.45M -52.57% | -48.45M -345.42% | -54.06M -43.25% | N/A | N/A | N/A | N/A |
All data in USD
10 analysts have analysed PSTX and the average price target is 9.18 USD. This implies a price decrease of -3.37% is expected in the next year compared to the current price of 9.5.
The consensus EPS estimate for the next earnings of POSEIDA THERAPEUTICS INC (PSTX) is -0.37 USD and the consensus revenue estimate is 17.34M USD.
The number of analysts covering POSEIDA THERAPEUTICS INC (PSTX) is 10.